NGS "COLORECTAL 2"panel : AKT1, ALK, BRAF, CTNNB1, EGFR, HER2, FBXW7, FGFR1, FGFR2, FGFR3, KIT, KRAS, MAP2K1, MET, NRAS, PDGFRA, PIK3CA, PTEN, SMAD4, STK11, TP53
Back to main menuEurofins Biomnis code
COLO2
Synonyms
- companion test
- NGS
- targeted therapy
- solid tumor
- oncology
Clinic significance
The NGS "COLO2" panel approach expands the range of mutations tested to the genes involved in resistance mechanisms for targeted therapies, emerging markers for targeted therapies and molecular targets that can be used when establishing a prognosis. It can also be supplemented with targeted FISH unit tests and the MSI test.
Prenalytics
- Tumoral block included in paraffin or slides (6 slides 5µm) or DNA extract
- Ambient temperature
Further information
- Attach the anatomopathological report
- Use the specific request form B9-INTGB: Oncology-Solid tumors
- The use of the S25UK transport bag is Mandatory.
Specific equipment available
S25 : Envelope Genetics and Molecular Oncology
Documents to download
Methodology
Targeted sequencing of cancer genes (NGS) : -Library : AmpliSeq Library PLUS for Illumina Custom Panel V1 - Amplicon-based targeted library preparation method -NGS Platform : MiSeq Illumina - Flowcell : microV2 (2x150pb) - Paired-end reads -Analysis software : Miseq control Software version 2.6.2.1 /SeqOne Platform v1.2 - CE Pipeline version : SomaVar v1.4 CE -Limit of detection : 5% -Minimum depth accepted : 500x -Human genome version : Hg19
Turnaround time
10 days (Results may require an extended turnaround time, one week, depending on the confirmation tests required by Sanger sequencing)
